紫杉醇联合奈达铂同步放疗治疗局部晚期非小细胞肺癌的临床疗效及安全性观察

摘要

Objective To study the clinical efficacy and safety of paclitaxel combined with nedaplatin and radiotherapy in treatment of locally advanced non-small cell lung cancer.Methods 104 patients with locally advanced non-small cell lung cancer in our hospital from January 2013 to October 2013 were randomly divided into the test group (n=53) and the control group (n=51).The control group was treated with radiotherapy and the test group was treated with paclitaxel combined with nedaplatin for concurrent radiotherapy.The clinical efficacy and safety of the two groups were observed.Results The RR was 75.48% in the test group and 56.86% in the control group (P<0.05).There was no significant difference in nausea and vomiting, granulocytopenia, hair loss, radioactive pneumonia and radiation esophagitis between the two groups (P>0.05).There was no significant difference in the KPS scores between the two groups (P>0.05).After treatment, there was no significant difference between the two groups (P>0.05).The survival rate of 1-year and 3-year was 88.68% and 64.15% in the test group, respectively, which were significantly higher than those in the control group (P<0.05).Conclusion Paclitaxel combined with nedaplatin and radiotherapy can significantly improve the treatment effect and the survival rate in treatment of locally advanced non-small cell lung cancer, without increasing the incidence of adverse reactions.%目的 观察紫杉醇联合奈达铂同步放疗治疗局部晚期非小细胞肺癌的临床疗效及安全性.方法 将我院2013年1月至2013年10月收治的晚期非小细胞肺癌患者104例,按照患者入院的顺序,随机将患者分为试验组(n=53)、对照组(n=51).对照组给予紫杉醇联合放疗治疗,试验组给予紫杉醇联合奈达铂同步放疗治疗.观察两组的临床疗效及治疗的安全性.结果 试验组近期疗效达RR为75.48%,对照组的RR仅为56.86%(P<0.05).两组患者发生恶心呕吐、粒细胞减少、脱发、放射性肺炎、放射性食管炎上均无显著差异(P>0.05).两组患者治疗前的KPS评分差异不明显(P>0.05),经治疗后,两组评分均有下降,但组间无显著差异(P>0.05).另外发现试验组1年、3年生存率分别为88.68%、64.15%均明显高于对照组,具有统计学意义的差异(P<0.05).结论 奈达铂联合紫杉醇同步放疗治疗局部晚期非小细胞肺癌,在不增加不良反应发生率的基础上,显著提高治疗效果,改善生存率.